Received Nov 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | 5AR2D | IM / LA |
Inappropriate age at vaccine administration; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 47-year-old male patient who received Men B NVS (Bexsero) (batch number 5AR2D, expiry date 31-DEC-2025) for prophylaxis. Concurrent medical conditions included diabetes (Diabetes) and immunocompromised. On 09-MAY-2025, the patient received the 1st dose of Bexsero (intramuscular, left arm). On 09-MAY-2025, an unknown time after receiving Bexsero, the patient experienced inappropriate age at vaccine administration (Verbatim: Inappropriate age at vaccine administration). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 06-NOV-2025 The medical assistant called to reported that an immunocompromised 48-year-old patient with diabetes received his first dose of Bexsero.
Diabetes (Diabetes); Immunocompromised